Kailera Therapeutics (KLRA) PE Ratio: History & Chart

Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.

The P/E ratio is N/A as of 2026-10-06T14:57:32.429Z.

Stored calculation inputs

Calculation as of: 2026-10-06T14:57:32.429Z.

Quote observation: 2026-10-06T14:55:30.000Z. Amounts in USD. The price header may show a later quote.

Quote price: 10.9228
Unrounded diluted TTM EPS · period ending 2026-06-30: N/A

FMP input reference: 610e9c20fcdf10729c15ba1bd616707a7081826ce2aba31979c935d5001cdfd8

Forward PE Ratio|PEG Ratio|P/B Ratio|EPS|All Metrics

KLRA PE Ratio Metrics

PE RATIO

N/A

KLRA Competitors' PE Ratio

KLRA

Kailera Therapeutics, Inc.

Current

Market Cap

$1.42B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

INBX

Inhibrx Biosciences Inc.

vs KLRA

Market Cap

$1.40B

PE Ratio

N/A

TTM Avg

0.13

3Y Avg

0.13

5Y Avg

0.13

ANAB

AnaptysBio, Inc.

vs KLRA

Market Cap

$1.44B

PE Ratio

9.04

TTM Avg

9.41

3Y Avg

9.41

5Y Avg

62.32

BRVE

Braveheart Bio, Inc.

vs KLRA

Market Cap

$1.45B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

MAZE

Maze Therapeutics, Inc.

vs KLRA

Market Cap

$1.46B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

HCSG

Healthcare Services Group, Inc.

vs KLRA

Market Cap

$1.46B

PE Ratio

12.46

TTM Avg

30.95

3Y Avg

30.73

5Y Avg

31.04

GHRS

GH Research PLC

vs KLRA

Market Cap

$1.47B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

COAG

Hemab Therapeutics Holdings, Inc. Common Stock

vs KLRA

Market Cap

$1.35B

PE Ratio

N/A

TTM Avg

N/A

3Y Avg

N/A

5Y Avg

N/A

CERT

Certara, Inc.

vs KLRA

Market Cap

$1.48B

PE Ratio

N/A

TTM Avg

174.30

3Y Avg

183.89

5Y Avg

183.89

OMER

Omeros Corporation

vs KLRA

Market Cap

$1.35B

PE Ratio

10.84

TTM Avg

10.02

3Y Avg

9.28

5Y Avg

5.37

NAME	MARKET CAP	PE RATIO	TTM	3Y	5Y
Kailera Therapeutics, Inc. (KLRA)	$1.42B	N/A	N/A	N/A	N/A
Inhibrx Biosciences Inc. (INBX)vs ›	$1.40B	N/A	0.13	0.13	0.13
AnaptysBio, Inc. (ANAB)vs ›	$1.44B	9.04	9.41	9.41	62.32
Braveheart Bio, Inc. (BRVE)vs ›	$1.45B	N/A	N/A	N/A	N/A
Maze Therapeutics, Inc. (MAZE)vs ›	$1.46B	N/A	N/A	N/A	N/A
Healthcare Services Group, Inc. (HCSG)vs ›	$1.46B	12.46	30.95	30.73	31.04
GH Research PLC (GHRS)vs ›	$1.47B	N/A	N/A	N/A	N/A
Hemab Therapeutics Holdings, Inc. Common Stock (COAG)vs ›	$1.35B	N/A	N/A	N/A	N/A
Certara, Inc. (CERT)vs ›	$1.48B	N/A	174.30	183.89	183.89
Omeros Corporation (OMER)vs ›	$1.35B	10.84	10.02	9.28	5.37

P/E Comparison

Trailing P/E

N/A

Forward P/E

N/A

Forward P/E Calculation

View All Analyst Estimates

Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.

Calculation:

Current Price

$10.92

÷

Forward EPS (Est.)

$-4.21

=

Forward P/E

N/A

Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.

PE Ratio Formula & Definition

PE Ratio = Share Price / Diluted EPS (TTM)

The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.

Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute

See the Lowest P/E Ratio Stocks ranking →

PE Ratio: N/A

KLRA PE Ratio Metrics

KLRA Competitors' PE Ratio

P/E Comparison

Forward P/E Calculation

PE Ratio Formula & Definition

Related Metrics